Compare American Electric Power Company Inc (AEP) vs GSK plc (GSK) Price & Performance

American Electric Power (AEP) trades at $123.89, up 0.85% today, with a bearish technical signal but strong analyst support. Recent Q2 2026 earnings missed estimates at $1.36 EPS versus $1.48 expected, though revenue grew 7% year-over-year. The company raised full-year 2026 operating EPS guidance to $6.25–$6.55, citing robust demand from data centers and a $78 billion capital plan. Valuation metrics include a P/E of 21.42 and P/B of 2.1, with a consensus price target of $140.89 implying 14% upside.

AEP's outlook is supported by contracted load growth and infrastructure investments, but risks include execution of its capital plan and interest expense pressures. The stock offers a dividend yield with an upcoming $0.95 payment. Analyst consensus is strongly bullish with 61% buy ratings, though technical indicators suggest near-term caution. Long-term growth targets of 7–9% annually provide a solid foundation for patient investors.

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.